BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide

BECTON DICKINSON & CO

2024-Q1 EPS reported $0.96 revenue$4,706,000,000

Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.
GAAP diluted EPS $0.96 vs. $1.70 prior year; adjusted diluted EPS $2.68 vs. $2.98.
Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance.
BD Medical launched SiteRite 9 Ultrasound System; BD Life Sciences received FDA clearance for MiniDraw Capillary Blood Collection System.
BD signed World Economic Forum's Zero Health Gaps Pledge, reinforcing health equity commitment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.